Sasaki Y, Kubo A, Kusakabe K, Masaki H, Endo K, Yamashita M, Nakajo M, Kaneko M
Department of Radiology, Faculty of Medicine, University of Tokyo.
Kaku Igaku. 1992 Sep;29(9):1083-98.
A phase III clinical study of 131I-metaiodobenzylguanidine (131I-MIBG) was performed in 66 patients with tumors of sympathetic and adrenomedullary origin, including 32 patients with suspected pheochromocytoma, 25 with suspected neuroblastoma, 7 pre- or postoperative medullary carcinoma of the thyroid and each with carcinoid and suspected Sipple's syndrome. A total of 150 sites which were confirmed for presence (72 sites) or absence (78 sites) of tumors were examined on 131I-MIBG scintigrams. True positive ratio of the scintigraphy was 84.7% (61/72) and true negative ratio was 94.9% (74/78). Positive scintigraphy was obtained in 86.5% (32/37) of pheochromocytoma, 78.6% (22/28) of neuroblastoma and 100% (6/6) of medullary carcinoma of the thyroid. Accumulation of 131I-MIBG was seen in 16.8% of normal adrenal glands. Neither adverse reactions nor abnormal laboratory findings were noted in relation to 131I-MIBG injections. Our study indicates that 131I-MIBG is a safe and clinically useful radiotracers for the visualization and localization of tumors of sympathetic and adrenomedullary origin.
对66例交感神经和肾上腺髓质来源肿瘤患者进行了131I-间碘苄胍（131I-MIBG）的III期临床研究，其中包括32例疑似嗜铬细胞瘤患者、25例疑似神经母细胞瘤患者、7例甲状腺髓样癌术前或术后患者，以及各1例类癌和疑似斯-琼综合征患者。在131I-MIBG闪烁扫描图上共检查了150个经证实有肿瘤（72个部位）或无肿瘤（78个部位）的部位。闪烁扫描的真阳性率为84.7%（61/72），真阴性率为94.9%（74/78）。嗜铬细胞瘤的闪烁扫描阳性率为86.5%（32/37），神经母细胞瘤为78.6%（22/28），甲状腺髓样癌为100%（6/6）。16.8%的正常肾上腺可见131I-MIBG聚集。未观察到与131I-MIBG注射相关的不良反应或实验室检查异常结果。我们的研究表明，131I-MIBG是一种安全且临床上有用的放射性示踪剂，可用于交感神经和肾上腺髓质来源肿瘤的可视化和定位。
